Insys agrees to $225 million settlement in DoJ opioid probe

6 June 2019

Opioid manufacturer Insys Therapeutics (Nasdaq: INSY) has agreed to a global resolution to settle the government’s separate criminal and civil investigations, the Department of Justice announced today.

As part of the criminal resolution, Insys will enter into a deferred prosecution agreement with the government, Insys’ operating subsidiary will plead guilty to five counts of mail fraud, and the company will pay a $2 million fine and $28 million in forfeiture. As part of the civil resolution, Insys agreed to pay $195 million to settle allegations that it violated the False Claims Act.

Market reaction to the settlement was positive, with Insys shares rising 3.7% to $0.86 by close of trading on Wednesday and up a further 4.4% to $0.90 in pre-market action today. Just a few weeks ago Insys parted company with its chief executive Saeed Motahari as the legal action was developing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK